Bronchogen: A Tetrapeptide Bioregulator Studied in Pulmonary Tissue

Research summary. Bronchogen is a four-amino-acid synthetic peptide (Ala-Glu-Asp-Leu, AEDL) that belongs to the family of "short peptide bioregulators" developed and characterised by the laboratory of Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. The bioregulator concept holds that very short peptides — typically dipeptides to tetrapeptides — can interact directly with DNA and chromatin to modulate tissue-specific gene expression. Bronchogen has been studied primarily in pulmonary tissue.

Molecular profile

• Sequence: Ala-Glu-Asp-Leu (AEDL)
• Molecular formula: C₁₈H₃₀N₄O₉
• Molecular weight: ~446.4 g/mol
• Class: Short peptide bioregulator (Khavinson peptides)
• Tissue association: Lung / bronchopulmonary system

Mechanism of action

The Khavinson laboratory has proposed that short peptide bioregulators act through direct interactions with the DNA double helix in a sequence-selective manner, modulating chromatin structure and the accessibility of specific gene loci. Reported mechanistic findings include:

• DNA stabilisation. Microcalorimetric studies have reported elevated DNA melting temperatures in the presence of Bronchogen, interpreted as a measure of duplex stabilisation [1].
• Tissue-selective gene expression. Cell-culture studies have reported upregulation of pulmonary lineage-associated transcription factors, including selected Hox genes and CXCL12, in lung-derived cell lines exposed to AEDL.
• Restoration of age-attenuated transcription. Effects in cell culture have been reported as more pronounced in older or senescent cell preparations than in young cells, consistent with the bioregulator-class hypothesis that these peptides preferentially restore expression of genes silenced by age-related chromatin condensation.

It is worth flagging that the molecular details of how a tetrapeptide reaches the nucleus and engages chromatin remain debated in the broader literature. Most of the supporting work has been published by the Khavinson group and collaborators; independent mechanistic confirmation is more limited than for Western-developed peptides.

Preclinical research highlights

Pulmonary epithelium and surfactant. Rat studies have reported that AEDL administration restores morphology of bronchial and alveolar epithelium in models of chronic obstructive pulmonary injury and increases pulmonary surfactant production, with associated reductions in alveolar surface tension and improved gas-exchange parameters [2].

Inflammation. Pulmonary inflammation models have shown attenuation of inflammatory infiltrate and tissue damage following Bronchogen administration, attributed in the source literature to modulation of NF-κB-related signalling.

Tissue-specific activity. Comparative studies in the Khavinson programme have reported that the activity of AEDL is largely restricted to lung tissue, with minimal off-target effects in unrelated tissues — a finding interpreted as evidence for the tissue-specificity built into the bioregulator concept.

Plant biology. A more unusual line of investigation has reported that Bronchogen, like the related bioregulator Epitalon, exhibits growth-regulatory activity in plant tissue cultures, with reported effects on the CLE peptide signalling pathway and KNOX1 transcription factors. While not therapeutically relevant, these findings underscore the proposed role of short peptides as DNA-interacting regulatory molecules across kingdoms.

Context: the Khavinson bioregulator family

Bronchogen is one of approximately a dozen tissue-targeted short peptide bioregulators developed in the Khavinson programme. Each peptide in the family is associated with a specific organ system — Cardiogen for the heart, Cortagen for the cortex, Vesugen for the vasculature, Pinealon for the pineal/CNS, and so on. The body of work has been published primarily in Russian biogerontology journals, with a smaller selection appearing in English-language Western journals. Independent Western replication has been uneven across the family, and the field remains a relatively isolated research programme rather than a mainstream pharmacological development pipeline.

Current research status

Bronchogen remains an investigational research peptide. It has not been approved as a therapeutic agent by any major regulatory authority and is not the subject of registered clinical trials in the U.S. or EU registries at the time of writing. It is studied as:

• A research tool for examining tissue-selective effects of short peptide bioregulators
• A reference compound in lung epithelial restoration models
• A geroprotective candidate in the broader Khavinson research programme on age-associated decline of organ function

Key takeaways for researchers

• Bronchogen is a tetrapeptide (Ala-Glu-Asp-Leu) developed in the Khavinson short-peptide bioregulator programme.
• Its proposed mechanism involves direct DNA interaction and tissue-selective transcriptional modulation in pulmonary tissue.
• Reported effects centre on epithelial restoration, surfactant production, and attenuation of inflammation in rodent lung models.
• The supporting literature originates primarily from a single research programme; independent validation is limited.
• Bronchogen is not an approved therapeutic.

References

1. Khavinson VK, Solovyev AY, Tarnovskaya SI, Lin'kova NS. Mechanism of biological activity of short peptides: cell penetration and epigenetic regulation of gene expression. Biology Bulletin Reviews. 2013;3(6):451–455.
2. Chalisova NI, Linkova NS, Nichik TE, Ryzhak AP. Geroprotective effect of bronchogen on culture of bronchial cells of young and old rats. Advances in Gerontology. 2014;4(2):124–127.

---

This article is provided for educational and research purposes only. Bronchogen is a research peptide. It is not an approved drug or therapeutic agent and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.